Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Abbott Diagnostics Technologies AS
AS
Active
Org 981363019
Kjelsåsveien 161, 0884
Oslo
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 1999 · 26 years old
287 employees
Monitor
Share
Norway
/
Companies
/
Manufacture of pharmaceutical preparations
/
Abbott Diagnostics Technologies AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
2.5B
1.9B
1.2B
0.6B
0B
2020: 0.9B
0.9B
2020
2021: 1.1B (+29% vs 2020)
1.1B
+29%
2021
2022: 1.1B (-7% vs 2021)
1.1B
-7%
2022
2023: 1.4B (+31% vs 2022)
1.4B
+31%
2023
2024: 2.0B (+44% vs 2023)
2.0B
+44%
2024
EBITDA
NOK millions
575M
431M
288M
144M
0M
2020: 193M
193M
2020
2021: 340M (+76% vs 2020)
340M
+76%
2021
2022: 121M (-64% vs 2021)
121M
-64%
2022
2023: 26M (-79% vs 2022)
26M
-79%
2023
2024: 462M (+1677% vs 2023)
462M
+1677%
2024
Income statement
NOK thousands
Item
2024
2023
2022
2021
2020
Revenue
1 985 798
1 380 148
1 050 798
1 134 159
876 848
Staff expenses
−0
−169 949
−147 214
−140 037
−159 252
EBITDA
462 445
26 385
121 306
340 091
192 720
Depreciation & amort.
−27 068
−32 889
−34 083
−31 811
−28 597
EBIT
435 377
−6 504
87 223
308 281
164 123
Net financials
54 527
85 266
58 436
4 987
5 345
Profit before tax
489 904
78 762
145 658
313 267
169 468
Tax
−0
16 481
31 225
−887 127
37 258
Net profit
382 416
62 281
114 433
3 342 489
132 210
Balance sheet
NOK thousands
Item
2024
2023
2022
2021
2020
Total assets
1 357 262
1 596 123
3 099 622
4 993 691
1 349 342
Equity
822 306
1 264 890
2 363 518
449 085
956 596
Long-term debt
0
0
314 888
397 018
120
Short-term debt
534 957
331 233
421 215
4 147 587
392 627
Total debt
534 957
331 233
736 104
4 544 606
392 746
Financial ratios
5-year trend
EBITDA margin
23,3 %
This company
15,8 %
Market median
This company
Market median
47% above market
2020
2024
Equity ratio
60,6 %
This company
38,2 %
Market median
This company
Market median
59% above market
2020
2024
Return on equity
46,5 %
This company
18,4 %
Market median
This company
Market median
153% above market
2020
2024
Net profit margin
19,3 %
This company
8,1 %
Market median
This company
Market median
138% above market
2020
2024
Asset turnover
1,46×
This company
1,12×
Market median
This company
Market median
30% above market
2020
2024
Debt / equity
0,65×
This company
0,62×
Market median
This company
Market median
5% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on Abbott Diagnostics Technologies AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
